Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Altimmune Inc (ALT)

Altimmune Inc (ALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 531,304
  • Shares Outstanding, K 71,125
  • Annual Sales, $ 430 K
  • Annual Income, $ -88,450 K
  • EBIT $ -100 M
  • EBITDA $ -102 M
  • 60-Month Beta 0.09
  • Price/Sales 1,193.76
  • Price/Cash Flow N/A
  • Price/Book 3.81

Options Overview Details

View History
  • Implied Volatility 88.81% ( +9.27%)
  • Historical Volatility 104.23%
  • IV Percentile 3%
  • IV Rank 14.07%
  • IV High 240.76% on 01/25/24
  • IV Low 63.93% on 09/25/24
  • Put/Call Vol Ratio 0.11
  • Today's Volume 8,076
  • Volume Avg (30-Day) 9,719
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 134,335
  • Open Int (30-Day) 123,217

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.34
  • Number of Estimates 4
  • High Estimate -0.27
  • Low Estimate -0.39
  • Prior Year -0.33
  • Growth Rate Est. (year over year) -3.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.45 +24.81%
on 11/04/24
11.16 -27.87%
on 11/13/24
+1.17 (+17.01%)
since 10/18/24
3-Month
5.86 +37.37%
on 10/01/24
11.16 -27.87%
on 11/13/24
+0.92 (+12.90%)
since 08/20/24
52-Week
2.48 +224.32%
on 11/22/23
14.84 -45.75%
on 02/28/24
+5.42 (+206.08%)
since 11/20/23

Most Recent Stories

More News
Altimmune, Inc. Reports Promising Phase 1b Trial Results for Pemvidutide in Reducing Cardio-Inflammatory and Hepato-Inflammatory Lipids in Patients with MASH

Pemvidutide showed significant reductions in inflammatory lipids, supporting its potential benefits for metabolic dysfunction-related conditions.Quiver AI SummaryAltimmune, Inc. announced favorable results...

ALT : 8.05 (+7.76%)
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024

ALT : 8.05 (+7.76%)
Altimmune (ALT) Stock Soars 27%: Phase 2 Data on Obesity Drug Ignites Market Optimism

In a remarkable turn of events, Altimmune (NASDAQ: ALT) witnessed a staggering 27% surge in its stock price this morning, fueled by promising clinical data from its Phase 2 trials and heightened investor...

ALT : 8.05 (+7.76%)
Altimmune Stock Goes Parabolic Following Q3 Results As CEO Touts 2025 As ‘Transformational Year:’ Retail Upbeat

Altimmune is betting big on its investigational metabolic diseases candidate pemvidutide.

ALT : 8.05 (+7.76%)
XBI : 94.01 (+0.90%)
IWM : 230.93 (+0.13%)
Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update

ALT : 8.05 (+7.76%)
Altimmune Stock Slides After New CFO Appointment, Retail Bulls Eye M&A Potential

The new hire’s background includes CFO roles at several biotech firms acquired in high-profile deals, such as Sirna Therapeutics (acquired by Merck) and ILEX Oncology (acquired by Genzyme).

IWO : 299.39 (+0.20%)
ALT : 8.05 (+7.76%)
IWM : 230.93 (+0.13%)
XBI : 94.01 (+0.90%)
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer

ALT : 8.05 (+7.76%)
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ALT : 8.05 (+7.76%)
MarketBeat Week in Review – 11/4 - 11/8

Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts

NVDA : 145.89 (-0.76%)
SMMT : 18.62 (-6.90%)
MRK : 97.44 (+0.93%)
ALT : 8.05 (+7.76%)
ENVX : 9.01 (+0.90%)
CCL : 25.08 (-0.20%)
COIN : 320.01 (-1.40%)
BMY : 57.88 (-0.60%)
FSLR : 184.84 (-1.35%)
SOUN : 6.44 (-1.08%)
QCOM : 154.27 (-6.34%)
INTC : 24.01 (-0.79%)
How Altimmune Could Grab a Big Chunk of the GLP-1 Market

Altimmune is working on a developmental weight loss drug that could have strong benefits for an important segment of GLP-1 users.

NVO : 105.27 (+2.57%)
LLY : 753.41 (+3.25%)
ALT : 8.05 (+7.76%)

Business Summary

Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 9.37
2nd Resistance Point 8.90
1st Resistance Point 8.47
Last Price 8.05
1st Support Level 7.57
2nd Support Level 7.10
3rd Support Level 6.67

See More

52-Week High 14.84
Fibonacci 61.8% 10.12
Fibonacci 50% 8.66
Last Price 8.05
Fibonacci 38.2% 7.20
52-Week Low 2.48

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar